Attovia Therapeutics Reports Q3 2026 Financials and Updates ATTO-1310 Clinical Data

Attovia Therapeutics, Inc. (Nasdaq: ATTO) reported its financial results for the third quarter ended September 30, 2026, and announced updates regarding its clinical pipeline. The company reported a cash, cash equivalent, and marketable securities balance of $395.9 million as of September 30, 2026. This represents a significant increase from $152.3 million as of December 31, 2025.

Regarding operations, the company reported no collaboration revenue for the third quarter of 2026, compared to $360,000 in the same period of the prior year. Research and development expenses for the third quarter of 2026 were $20.3 million, while general and administrative expenses were $4.7 million. The company recorded a net loss of $22.3 million for the third quarter of 2026.

In clinical news, Attovia announced positive topline 12-week results from its Phase 1b study of ATTO-1310, a next-generation anti-IL-31 ATTOBODY-based therapy. The study was conducted in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD). The data demonstrated rapid, clinically meaningful itch relief and improvements in skin disease severity that deepened through Week 12 following a single dose.

In the CP cohort, 82% of ATTO-1310-treated patients achieved a reduction in itch of at least 4 points on the Peak Pruritus Numerical Rating Scale (PP-NRS4) at Week 12, compared to 22% with placebo. In the high-itch AD cohort, 44% of treated patients achieved PP-NRS4 at Week 12. Additionally, 44% of treated patients in the AD cohort achieved at least a 75% improvement on the Eczema Area and Severity Index (EASI-75) and 39% achieved clear or almost clear skin on the validated Investigator Global Assessment (vIGA 0/1).

Safety data indicated that ATTO-1310 was generally well tolerated. A single subcutaneous dose led to rapid, sustained suppression of circulating IL-31 of approximately 95% through Week 12, supporting the potential for quarterly dosing. The company plans to initiate two Phase 2 trials, the ATTUNE-CPUO and ATTUNE-AD trials, in the first half of 2027. The company also expects to initiate Phase 1 trials for ATTO-2306 and ATTO-1091 in the first half of 2027.